X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2900) 2900
Newsletter (157) 157
Newspaper Article (111) 111
Publication (36) 36
Book Chapter (20) 20
Magazine Article (6) 6
Dissertation (4) 4
Conference Proceeding (3) 3
Streaming Video (3) 3
Transcript (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ticagrelor (3065) 3065
clopidogrel (1957) 1957
humans (1264) 1264
prasugrel (1081) 1081
cardiac & cardiovascular systems (999) 999
percutaneous coronary intervention (686) 686
male (678) 678
aspirin (669) 669
acute coronary syndromes (649) 649
female (612) 612
acute coronary syndrome (601) 601
adenosine - analogs & derivatives (567) 567
middle aged (537) 537
platelet aggregation inhibitors - therapeutic use (518) 518
aged (501) 501
treatment outcome (454) 454
cardiac patients (416) 416
coronary heart disease (409) 409
ticlopidine - analogs & derivatives (407) 407
antiplatelet therapy (386) 386
pharmacology & pharmacy (386) 386
care and treatment (385) 385
myocardial infarction (364) 364
platelet inhibition (359) 359
platelet aggregation inhibitors - adverse effects (350) 350
acute coronary syndrome - drug therapy (332) 332
research (325) 325
outcomes (318) 318
platelet aggregation inhibitors - administration & dosage (318) 318
cardiology (310) 310
risk factors (308) 308
peripheral vascular disease (300) 300
heart attacks (292) 292
myocardial-infarction (292) 292
abridged index medicus (290) 290
thrombosis (283) 283
adenosine - therapeutic use (280) 280
blood platelets (272) 272
mortality (272) 272
intervention (266) 266
dual antiplatelet therapy (263) 263
medical research (263) 263
hematology (257) 257
purinergic p2y receptor antagonists - therapeutic use (257) 257
medicine, experimental (250) 250
ticlopidine - therapeutic use (250) 250
cardiovascular diseases (245) 245
inhibition (245) 245
analysis (242) 242
stroke (238) 238
patients (234) 234
drug therapy (233) 233
bleeding (232) 232
transluminal angioplasty (226) 226
elevation myocardial-infarction (215) 215
therapy (214) 214
heart attack (211) 211
medicine, general & internal (210) 210
hemorrhage - chemically induced (207) 207
cangrelor (199) 199
adenosine - adverse effects (196) 196
adenosine - administration & dosage (194) 194
cardiovascular (192) 192
clinical trials (192) 192
dosage and administration (192) 192
cardiovascular disease (189) 189
double-blind (188) 188
drug therapy, combination (188) 188
time factors (186) 186
purinergic p2y receptor antagonists - administration & dosage (183) 183
risk (183) 183
acute myocardial-infarction (181) 181
aggregation (180) 180
blood platelets - drug effects (176) 176
purinergic p2y receptor antagonists - adverse effects (176) 176
adenosine (168) 168
management (166) 166
prasugrel hydrochloride (165) 165
coronary artery disease (163) 163
prospective studies (163) 163
platelet reactivity (161) 161
platelet aggregation - drug effects (155) 155
prevention (154) 154
safety (149) 149
platelets (147) 147
stents (147) 147
trial (147) 147
aspirin - therapeutic use (146) 146
adult (143) 143
platelet aggregation inhibitors - pharmacology (142) 142
coronary vessels (141) 141
ischemia (139) 139
ticlopidine - adverse effects (139) 139
p2y (135) 135
pharmacokinetics (132) 132
ticlopidine - administration & dosage (132) 132
platelet function tests (129) 129
angioplasty (128) 128
physical fitness (127) 127
artery-disease (126) 126
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3103) 3103
German (51) 51
French (36) 36
Russian (30) 30
Spanish (27) 27
Czech (13) 13
Polish (12) 12
Portuguese (8) 8
Chinese (7) 7
Turkish (6) 6
Japanese (4) 4
Korean (4) 4
Italian (3) 3
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2019, Volume 381, Issue 21, pp. 2032 - 2042
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 381, Issue 16, pp. 1524 - 1534
Journal Article
European heart journal, ISSN 1522-9645, 2009, Volume 30, Issue 16, pp. 1964 - 1977
Currently, clopidogrel is recommended for treatment of patients with acute coronary syndrome and/or percutaneous coronary intervention. However, the delayed... 
Prasugrel | Clopidogrel | Thienopyridine | Cangrelor | Ticagrelor | Purinoceptor P2Y
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 08/2018, Volume 118, Issue 8, pp. 1409 - 1418
Abstract Morphine delays oral P2Y 12 platelet inhibitor absorption and is associated with adverse outcomes after myocardial infarction. Consequently, many... 
Cellular Haemostasis and Platelets | platelet inhibition | percutaneous coronary intervention | ticagrelor | fentanyl | CANGRELOR | MORPHINE | CONSCIOUS SEDATION | CLOPIDOGREL | INTRAVENOUS FENTANYL | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | PRASUGREL | ABSORPTION | HEMATOLOGY | ANALGESIA | Fentanyl - administration & dosage | Fentanyl - adverse effects | Purinergic P2Y Receptor Antagonists - administration & dosage | Humans | Middle Aged | Male | Purinergic P2Y Receptor Antagonists - adverse effects | Percutaneous Coronary Intervention - instrumentation | Ticagrelor - adverse effects | Analgesics, Opioid - adverse effects | Drug Interactions | Time Factors | Platelet Aggregation Inhibitors - administration & dosage | Platelet Function Tests | Ticagrelor - administration & dosage | Female | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Stents | Platelet Aggregation Inhibitors - adverse effects | Gastrointestinal Absorption - drug effects | Ticagrelor - pharmacokinetics | Administration, Oral | Risk Factors | Purinergic P2Y Receptor Antagonists - pharmacokinetics | Treatment Outcome | Coronary Angiography | Administration, Intravenous | Coronary Artery Disease - diagnostic imaging | Baltimore | Coronary Artery Disease - therapy | Analgesics, Opioid - administration & dosage | Aged | Percutaneous Coronary Intervention - adverse effects
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 381, Issue 14, pp. 1309 - 1320
Patients with stable coronary artery disease and diabetes were randomly assigned to receive either ticagrelor plus aspirin or placebo plus aspirin. At 40... 
MEDICINE, GENERAL & INTERNAL | CLOPIDOGREL | DUAL ANTIPLATELET THERAPY | MYOCARDIAL-INFARCTION | CARDIOVASCULAR EVENTS | CLINICAL BENEFIT | PLATELET INHIBITION | PRASUGREL | COLLABORATIVE METAANALYSIS | SECONDARY PREVENTION | 60 MG | Myocardial Infarction - epidemiology | Follow-Up Studies | Humans | Middle Aged | Hemorrhage - mortality | Male | Incidence | Drug Therapy, Combination - adverse effects | Ticagrelor - adverse effects | Aspirin - adverse effects | Female | Stroke - epidemiology | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor - therapeutic use | Diabetes Mellitus, Type 2 - complications | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Hemorrhage - epidemiology | Kaplan-Meier Estimate | Treatment Outcome | Coronary Artery Disease - drug therapy | Coronary Artery Disease - mortality | Coronary Artery Disease - complications | Diabetes Mellitus, Type 2 - mortality | Aged | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Diabetes Mellitus, Type 2 - drug therapy | Control | Usage | Safety and security measures | Diabetes | Cardiovascular diseases | Drug therapy | Ticagrelor | Coronary heart disease | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Diabetes mellitus | Coronary artery | Cardiovascular disease | Thrombosis | Hemorrhage | Thrombolysis | Bleeding | Design | Ischemia | Blood platelets | Coronary vessels | Population | Diabetes mellitus (non-insulin dependent) | Heart diseases | Research centers | Life Sciences | Human health and pathology
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 11/2016, Volume 115, Issue 6, pp. 1079 - 1088
Summary Ticagrelor is an antagonist of the platelet P2Y 12 receptor for ADP, approved for the prevention of thromboembolic events in patients with acute... 
Cellular Haemostasis and Platelets | Megakaryocytes | Platelets | Ticagrelor | P2Y
Journal Article
Revista española de cardiologia, ISSN 0300-8932, 11/2017, Volume 70, Issue 11, pp. 952 - 959
Introduction and objectives The incorporation of the new antiplatelet agents (NAA) prasugrel and ticagrelor into routine clinical practice is irregular and... 
Prasugrel | Propensity score | Registry | Ticagrelor | Real world
Journal Article
Chinese Medical Journal, ISSN 0366-6999, 9/2018, Volume 131, Issue 17, pp. 2017 - 2024
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 2017, Volume 117, Issue 4, pp. 718 - 726
Summary Oral administration of crushed ticagrelor tablets turned out to be an efficacious method that improves its pharmacokinetics and pharmacodynamics. This... 
Cellular Haemostasis and Platelets | MORPHINE | PRIMARY PCI | sublingual | platelets | TABLETS | crushed ticagrelor administration | DRUGS | RAPID ACTIVITY | STEMI | PERIPHERAL VASCULAR DISEASE | PRASUGREL | unstable angina | HEALTHY-VOLUNTEERS | ABSORPTION | Ticagrelor | HEMATOLOGY | ELEVATION MYOCARDIAL-INFARCTION
Journal Article
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 09/2009, Volume 7, Issue 9, pp. 1556 - 1565
Background: P2Y12 plays an important role in regulating platelet aggregation and function. This receptor is the primary target of thienopyridine antiplatelet... 
AZD6140 | P2Y12 | AZ11931285 | ticagrelor | ADP | 2MeS‐ADP | platelet aggregation | 2MeS-ADP | Platelet aggregation | Ticagrelor
Journal Article